Greyson International is an R&D pharmaceutical company that develops enhanced, patent protected dermatology and healthcare products including products and various other medical treatments using its patented technology Trilexon®. Greyson International's primary objective is to license these prescription and over-the-counter products into the $65 billion global dermatology market and other medical markets. Potential licensees include international and multi-national pharmaceutical, cosmetic, skincare and consumer goods companies seeking new products, product enhancements or life cycle management for their existing products.